Australia's Telix Pharmaceuticals rises on US code approval for imaging agent

** Shares of Telix Pharmaceuticals TLX rise as much as 7% to A$25.71, logging their biggest intraday pct gain since May 13

** Stock hits highest level since June 19

** TLX among top performers on the ASX 200 benchmark, which is down 0.3%

** Biopharmaceutical firm says its prostate-specific membrane antigen (PSMA) PET imaging agent, Gozellix, granted permanent healthcare common procedure coding system (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services

** Code assignment supports reimbursement for Gozellix, support clinical adoption of and expanded access to PSMA PET imaging

** Stock up 4.4% YTD